Defusing SARS-CoV-2: Emergency Brakes in a Vaccine Failure Scenario

Ariel Fernández

doi:10.1021/acsptsci.0c00152

Defusing SARS-CoV-2: Emergency Brakes in a Vaccine Failure Scenario

ACS Pharmacol Transl Sci. 2020 Oct 15;3(6):1425-1426. doi: 10.1021/acsptsci.0c00152. eCollection 2020 Dec 11.

Author

Ariel Fernández^{1

2}

Affiliations

¹ Daruma Institute for AI in Pharmaceutical Research, AF Innovation Pharma Consultancy, 4000 Pemberton Court, Winston-Salem, North Carolina 27106, United States.
² CONICET, National Research Council for Science and Technology, Buenos Aires 1033, Argentina.

Abstract

Deactivation of primed SARS-CoV-2 prior to cell entry constitutes an emergency brake in COVID-19 infection if vaccine-induced antibodies fail to block recognition of the human angiotensin-converting enzyme 2 (hACE2) receptor. The timing and locus for the therapeutic intervention are dictated by the cell entry mechanism and by the selective advantage of the dominant D614G mutation.